The Medical Industry’s Focus on Longevity

I can’t stop thinking about that particular moment. Several hundred scientists, medical professionals, and businesspeople convened in Cascais, a sun-bleached coastal town west of Lisbon, in May 2023 for what was billed as the first Longevity Med Summit. The Atlantic wind blew in off the water outside the conference room. Inside, the discussion was about redefining aging itself, which is far more significant than any one medication or treatment. Not as something that must be endured, but rather as a biological process that could be slowed, molded, or even partially reversed with sufficient creativity and investment.

That meeting was a sign that something that was already underway had reached critical mass rather than the beginning of something entirely new. In recent years, the medical field has shifted toward longevity as a serious clinical and commercial frontier, both visibly and financially. The figures are startling: in 2024 alone, startups with a longevity focus raised $8.5 billion in venture capital. By the end of this decade, the overall market, which is currently valued at about $5.3 trillion in 2023, is expected to grow to $8 trillion. These are not projections from futurist think tanks. Hospital systems and pharmaceutical executives are now developing strategies based on these figures.

It wasn’t always the case, but the science has been keeping up with the ambition. Serious longevity research was conducted on the periphery for decades by researchers who frequently had to defend their credibility in grant applications. After scientists started mapping what they refer to as the hallmarks of aging—a collection of cellular and molecular processes that cause age-related decline—that significantly changed. By 2023, the framework had grown from nine in 2013 to twelve, including gut microbiome disruption, chronic inflammation, and impaired cellular cleanup mechanisms. This expansion is significant because it provided physicians and pharmaceutical companies with a more tangible map that they could actually target.

The role of GLP-1 receptor agonists, such as Ozempic, Wegovy, and Mounjaro, has been perhaps the most surprising development in the longevity debate. They started out as drugs for diabetes and weight loss, but the information that has since been gathered about them has been subtly remarkable. Even in individuals without diabetes, these medications reduced major cardiovascular events by thirteen to twenty-six percent, according to landmark trials. They exhibit early indications of neuroprotective qualities, seem to lessen chronic inflammation, and enhance kidney function. According to research published between 2024 and 2025, a related class of medications called SGLT2 inhibitors could lengthen telomeres, one of the more reliable indicators of biological age, in a sizable portion of patients after just 26 weeks. It was not anticipated that weight-loss medications would resemble aging treatments. And yet, here we are.

Businesses like Novo Nordisk and Eli Lilly have taken note. It is a significant change that both have begun to frame their GLP-1 programs in terms of healthspan extension. Unlike lifespan, healthspan describes the number of years a person is in true good health, meaning they are not just alive but also functioning well. This distinction is crucial to longevity medicine’s positioning, and it’s important because the debate goes beyond morality and philosophy. Long-term illness and dependency in later life are costly, both socially and economically, in ways that the world’s aging populations are just now starting to fully understand.

In the meantime, Novartis established a whole division specifically focused on aging biology called Diseases of Aging and Regenerative Medicine, or DARe. The company announced a $550 million partnership with BioAge Labs in late 2024. BioAge Labs’ methodology entails identifying individuals who age exceptionally well, measuring thousands of biological molecules over time, and using computational analysis to extract potential drug targets. It’s a method that reverses the conventional approach: you begin with exceptional health and attempt to understand why it persists, rather than beginning with disease and working backward. It has a detective-like quality to it.

AI has become more than just a catchphrase. Phase IIa results for a medication created solely with generative AI to treat idiopathic pulmonary fibrosis, a condition with close ties to aging biology, were released by Insilico Medicine in September 2024. Over a twelve-week period, patients receiving the highest dose demonstrated a significant improvement in lung function, whereas the placebo group experienced a decline. From target identification to clinical readout, the drug reached this stage in less than four years, shortening a timeframe that typically takes much longer. The following June, the findings were published in Nature Medicine. Although the proof of concept is difficult to reject, it is still unclear if this type of compression will hold across other targets.

Human trials have begun for senolytic therapies, which are medications intended to eliminate what scientists refer to as “zombie cells,” senescent cells that remain in tissue and release inflammatory chemicals. In June 2025, Rubedo Life Sciences administered its first dose to a patient using a mechanism that eliminates all senescent cells without regard to their toxicity. Although the trial is still in its early stages, the introduction of human testing following years of convincing animal data feels like a true turning point. Senolytics may fail in humans, as many promising methods have. However, investors appear to think differently, and the scientific justification is still among the most logical in the field.

The way that the true purpose of medicine is framed has probably changed the most. The medical system was structured around disease for the majority of the twentieth century: you became ill, sought treatment, and either recovered or did not. A different question is posed by longevity medicine: what if the system intervened earlier, treating the underlying mechanisms of decline before disease took hold and tracking biological age instead of waiting for clinical symptoms? Glycome analysis, DNA methylation clocks, and gut microbiome profiling are all being investigated as methods to measure an individual’s actual rate of aging, independent of their birth certificate. Diagnostics are also heading in this direction.

Saying that all of this is simple progress would be too simple. Longevity clinics are becoming more and more common in places like Singapore, Dubai, and London. They combine aggressive marketing with respectable science in ways that can be quite difficult to understand. Some provide test panels whose clinical utility is still unknown. Others market protocols that are sensible lifestyle choices wrapped in upscale packaging, such as supplement regimens, continuous glucose monitoring, and sleep optimization. The field is messy enough to encourage skepticism and serious enough to demand attention. It’s difficult to avoid experiencing a sort of dual awareness as you watch this unfold: both the hype and the actual event are real.

Unquestionably, the medical industry’s emphasis on longevity has gone too far. This discussion is no longer taking place on the fringes of reputable science. Boardrooms, regulatory talks, clinical trials, and the business plans of companies that invest billions in drug development are all places where it occurs. Whether we are ready for it or not, the question of how long and well humans can live, as well as what medicine can legitimately do about it, is now a mainstream medical question.